Q1 2025 Theravance Biopharma Inc Earnings Call Transcript

May 8, 2025 / 09:00 PM GMT

Release Date Price: $9.9 (-0.90%)

Transcript 10-Q8-K

Key Points

Positve

Theravance Biopharma Inc (TBPH) reported a 6% increase in net sales for the first quarter, driven by demand growth and favorable pricing.
Hospital doses increased by 48% year-over-year, indicating strong momentum in the hospital channel.
The company is on track to achieve a $50 million milestone from Royalty Pharma in 2025 due to strong sales of Trilogy.
Theravance Biopharma Inc (TBPH) ended the quarter with $131 million in cash and no debt, highlighting a strong financial position.
The company is making significant progress in the Cypress trial, with expectations to complete enrollment by late summer and topline data available six months later.

Negative

Operating expenses increased to $25 million this quarter, driven by higher R&D and SG&A costs.
There are ongoing litigation issues with three outstanding litigants regarding paragraph IV filings for UPLRY.
The company anticipates a one-time tax payment in Q2 related to the $50 million Trilogy milestone, which will impact cash burn.
The manufacturing of Amproloxetine's API is outside the United States, which may require adjustments due to potential policy changes.
Despite strong hospital performance, there is a need for improved transition of care to ensure hospital prescriptions translate into chronic prescriptions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TBPH.OQ - Theravance Biopharma Inc
Q1 2025 Theravance Biopharma Inc Earnings Call
May 08, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, la, ladies and gentlemen. Good afternoon. I'd like to welcome everyone to the Fair Evans BioPharma first quarter 2025 conference call.

During the presentation, all participants will be in a listen-only mode. A question session will follow the company's formal remarks. To ask a question, press the star key followed by the digit 1 on your phone. Again, that is 1 to ask a question.

If listening via webcast, please mute audio on your webcast device before asking a question over the phone.

I will repeat these instructions after management completes their prepared remarks. Also, today's conference is being recorded.

And now I would like to turn the call over to Rick Buntingham, Chief

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.